CELF2 and hepatocellular carcinoma: CELF2 has been shown to be a miR-95 downstream target and Brucein-D, a drug that targets miR-95 and reduces hepatocellular carcinoma (HCC) cell proliferation in vitro and tumor growth in vivo [137].